


bpV(phen)

Cat. No.:	HY-136065
CAS No.:	42494-73-5
Molecular Formula:	C ₁₂ H ₈ KN ₂ O ₅ V
Molecular Weight:	350.24
Target:	PTEN; Phosphatase; Parasite; Apoptosis
Pathway:	PI3K/Akt/mTOR; Metabolic Enzyme/Protease; Anti-infection; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	bpV(phen), an insulin-mimetic agent, is a potent protein tyrosine phosphatase (PTP) and PTEN inhibitor with IC ₅₀ s of 38 nM, 343 nM and 920 nM for PTEN, PTP-β and PTP-1B, respectively. bpV(phen) inhibits proliferation of the protozoan parasite <i>Leishmania</i> in vitro. bpV(phen) strongly induces the secretion of a large number of chemokines and pro-inflammatory cytokines, and it activates a Th1-type pathway (IL-12, IFNγ). bpV(phen) can also induce cell apoptosis, and has anti-angiogenic and anti-tumor activity ^{[1][2][3][4][5]} .														
IC₅₀ & Target	IC ₅₀ : 38 nM (PTEN), 343 nM (PTP-β) and 920 nM (PTP-1B) ^[3] Parasite <i>Leishmania</i> ^[2] Apoptosis ^[1]														
In Vitro	<p>bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment causes a further decrease of cell viability in H/R-injured H9c2 cells^[1].</p> <p>bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment increases the apoptosis of H/R-injured H9c2 cells^[1].</p> <p>bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment significantly promotes the accumulation of cytoplasmic Cytochrome C in H/R-injured H9c2 cells^[1].</p> <p>After stimulation of bpV(phen), PTEN-induced putative kinase protein 1 (PINK1)/Parkin-mediated mitophagy is inhibited^[1].</p> <p>bpV(phen) is an insulin-mimetic agent following insulin-receptor tyrosine kinase hyperphosphorylation and activation^[4].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Hypoxia/reoxygenation (H/R)-injured H9c2 cells</td> </tr> <tr> <td>Concentration:</td> <td>5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)</td> </tr> <tr> <td>Result:</td> <td>Caused a further decrease of cell viability.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Hypoxia/reoxygenation (H/R)-injured H9c2 cells</td> </tr> <tr> <td>Concentration:</td> <td>5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)</td> </tr> </table>	Cell Line:	Hypoxia/reoxygenation (H/R)-injured H9c2 cells	Concentration:	5 μM	Incubation Time:	24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)	Result:	Caused a further decrease of cell viability.	Cell Line:	Hypoxia/reoxygenation (H/R)-injured H9c2 cells	Concentration:	5 μM	Incubation Time:	24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)
Cell Line:	Hypoxia/reoxygenation (H/R)-injured H9c2 cells														
Concentration:	5 μM														
Incubation Time:	24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)														
Result:	Caused a further decrease of cell viability.														
Cell Line:	Hypoxia/reoxygenation (H/R)-injured H9c2 cells														
Concentration:	5 μM														
Incubation Time:	24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)														

Result:	Increased the apoptosis of H/R-injured H9c2 cells.
---------	--

Western Blot Analysis^[1]

Cell Line:	Hypoxia/reoxygenation (H/R)-injured H9c2 cells
------------	--

Concentration:	5 μ M
----------------	-----------

Incubation Time:	24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes)
------------------	---

Result:	Showed an increased release of Cytochrome C.
---------	--

In Vivo

bpV(phen) (5 mg/kg; intraperitoneal injection; daily; for 38 days; male BALB/c nude (nu/nu) athymic mice) treatment causes a significant reduction in average tumor volume^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c nude (nu/nu) athymic mice (6-7 weeks old) injected with PC-3 cells ^[2]
---------------	---

Dosage:	5 mg/kg
---------	---------

Administration:	Intraperitoneal injection; daily; for 38 days
-----------------	---

Result:	Caused a significant reduction in average tumor volume.
---------	---

CUSTOMER VALIDATION

- Biochem Bioph Res Co. 2020 Sep 3;529(4):1045-1052.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Tang W, et al. PTEN-mediated mitophagy and APE1 overexpression protects against cardiac hypoxia/reoxygenation injury. *In Vitro Cell Dev Biol Anim.* 2019 Oct;55(9):741-748.

[2]. Caron D, et al. Protein tyrosine phosphatase inhibition induces anti-tumor activity: evidence of Cdk2/p27 kip1 and Cdk2/SHP-1 complex formation in human ovarian cancer cells. *Cancer Lett.* 2008 Apr 18;262(2):265-75.

[3]. Schmid AC, et al. Bisperoxovanadium compounds are potent PTEN inhibitors. *FEBS Lett.* 2004 May 21;566(1-3):35-8.

[4]. Band CJ, et al. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen). *Mol Endocrinol.* 1997 Dec;11(13):1899-910.

[5]. Chen Q, et al. Potassium Bisperoxo(1,10-phenanthroline)oxovanadate (bpV(phen)) Induces Apoptosis and Pyroptosis and Disrupts the P62-HDAC6 Protein Interaction to Suppress the Acetylated Microtubule-dependent Degradation of Autophagosomes. *J Biol Chem.* 2015 Oct 23;290(43):26051-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA